fluorouracil - CISMeF

Preferred Label : fluorouracil;

MeSH definition : A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.;

MeSH synonym : 5-fu; 5 fluorouracil; 5-fluorouracil; fluoruracil; 5fu;

CISMeF synonym : pharmacia brand of fluorouracil; fluorouracil teva brand; dermik brand of fluorouracil; dermatech brand of fluorouracil; roche brand of fluorouracil; ICN brand of fluorouracil; CSP brand of fluorouracil; allergan brand of fluorouracil; gry brand of fluorouracil; dakota brand of fluorouracil; ferrer brand of fluorouracil; pharmachemie brand of fluorouracil monosodium salt; haemato brand of fluorouracil; neocorp brand of fluorouracil; onkoworks brand of fluorouracil; ribosepharm brand of fluorouracil; biosyn brand of fluorouracil; riemser brand of fluorouracil; medac brand of fluorouracil; hexal brand of fluorouracil; teva brand of fluorouracil;

MeSH hyponym : adrucil; fluorouracil mononitrate; onkofluor; Fluorouracil-GRY; fluorouracilo ferrer far; fluorouracil potassium salt; fluorouracile dakota; efudix; 5-HU hexal; neofluor; 5-FU lederle; 5-Fluorouracil-biosyn; 5-FU medac; carac; fluorouracil monosodium salt; haemato-fu; fluoroplex; fluracedyl; fluorouracil monopotassium salt; ribofluor; 5 FU Lederle; 5 FU Medac; 5 HU Hexal; Fluoro-Uracile ICN; Fluoro Uracile ICN; Efudex; Flurodex; Fluorouracil GRY; Dakota, Fluorouracile; Haemato FU; 5 Fluorouracil Biosyn;

MeSH CAS label : 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-;

MeSH Related Number : fluorouracil mononitrate; fluorouracil monopotassium salt; fluorouracil monosodium salt; fluorouracil potassium salt; 10318-20-4 (mono-Na salt); 51-21-8 (Fluorouracil); 57050-04-1 (K salt); 57172-36-8 (mononitrate); 68021-61-4 (mono-K salt);

Registry Number MeSH : 51-21-8;

Related CAS MeSH : 57172-36-8 (Fluorouracil mononitrate); 68021-61-4 (Fluorouracil monopotassium salt); 10318-20-4 (Fluorouracil monosodium salt); 57050-04-1 (Fluorouracil potassium salt);

Wikipedia link : https://en.wikipedia.org/wiki/Fluorouracil;

Codes EINECS : 200-085-6;

Is substance : O;

UNII : U3P01618RT;

InChIKey : GHASVSINZRGABV-UHFFFAOYSA-N;

Details

Origin ID

D005472;

UMLS CUI

C0016360;

ATC code(s)
- fluorouracil, combinations [ATC Code]
ATC code(s)
- fluorouracil [ATC Code]
- fluorouracil, combinations [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- fluorouracil [Substance BNPC]
Currated CISMeF NLP mapping
- Fluorouracil [ICD-11 Extension code]
- Fluorouracil [LOINC component]
- Fluorouracil [ICHI extension code]
- Fluorouracil [NCIt concept]
- Fluorouracil (substance) [SNOMED CT concept]
- fluorouracil [SNOMED Notion]
False automatic mappings
- Caracal caracal (organism) [SNOMED CT concept]
Pharmacological action(s)
- antimetabolites, antineoplastic [MeSH Descriptor]
- immunosuppressive agents [MeSH Descriptor]
Record concept(s)
- 5-FU lederle [MeSH concept]
- 5-FU medac [MeSH concept]
- 5-Fluorouracil-biosyn [MeSH concept]
- 5-HU hexal [MeSH concept]
- Fluorouracil-GRY [MeSH concept]
- adrucil [MeSH concept]
- carac [MeSH concept]
- efudix [MeSH concept]
- fluoroplex [MeSH concept]
- fluorouracil [MeSH concept]
- fluorouracil mononitrate [MeSH concept]
- fluorouracil monopotassium salt [MeSH concept]
- fluorouracil monosodium salt [MeSH concept]
- fluorouracil potassium salt [MeSH concept]
- fluorouracile dakota [MeSH concept]
- fluorouracilo ferrer far [MeSH concept]
- fluracedyl [MeSH concept]
- haemato-fu [MeSH concept]
- neofluor [MeSH concept]
- onkofluor [MeSH concept]
- ribofluor [MeSH concept]
Related MeSH Supplementary Concept(s)
- (5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl) methyl-(4-((2-aminophenyl)carbamoyl)phenyl)carbamate [MeSH Supplementary Concept]
- (5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl-4-((2-aminophenyl)carbamoyl)benzylcarbamate [MeSH Supplementary Concept]
- 1,3-didecanoyl-2-(6-(5-fluorouracil-1-yl)carbonylamino)glyceride [MeSH Supplementary Concept]
- 1-((1,3-dihydroxy-2-propoxy)methyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-((2-(2-chloroethoxy)ethoxy)methyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-((2-chloroethoxy)methyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-((2-hydroxyethoxy)methyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-((3-(2-hydroxyethoxy)-1-isopropoxy)propyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-((3-(3-chloro-2-hydroxyproxy)-1-methoxy)propyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-((6-chlorohexyloxy)methyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-(2'-tetrahydrothienyl) 5-fluorouracil [MeSH Supplementary Concept]
- 1-(2'-tetrahydrothienyl)-5 fluorouracil-1-'1'-dioxide [MeSH Supplementary Concept]
- 1-(2'-tetrahydrothienyl)-5-fluorouracil-1'-oxide [MeSH Supplementary Concept]
- 1-(2,4-dioxo-5-fluoro-(1H,3H)-pyrimidin-1-yl)-2-(2,3-dihydroxy-2-buten-4-olidylidene)ethane [MeSH Supplementary Concept]
- 1-(3-carboxypropylcarbamoyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-(4'-C-cyano-4'-C-deoxy)-5-fluorouracil [MeSH Supplementary Concept]
- 1-(4'-C-cyanomannopyranosyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-(5'-fluoro-6'-hydroxy-5',6'-dihydrouracil-5'-yl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-(5'-hydroxyhexylcarbamoyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-(5'-oxohexylcarbamoyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-(carboxypropylcarbamoyl)-5-fluorouracil lipolyl ester [MeSH Supplementary Concept]
- 1-(ethoxycarbonyloxymethyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-(phenoxycarbonyloxymethyl)-5-fluorouracil [MeSH Supplementary Concept]
- 1-acetyl-3,2-toluyl-5-fluorouracil [MeSH Supplementary Concept]
- 1-arabinofuranosyl-5-fluorouracil [MeSH Supplementary Concept]
- 1-carboxylmethyl-5-fluorouracil [MeSH Supplementary Concept]
- 1-ethoxymethyl-5-fluorouracil [MeSH Supplementary Concept]
- 1-phenethylcarbamoyl-5-fluorouracil [MeSH Supplementary Concept]
- 1-phthalidyl-5-fluorouracil [MeSH Supplementary Concept]
- 13F-1 compound [MeSH Supplementary Concept]
- 2'-deoxy-2'-18F-fluoro-5-fluoro-1-beta-D-arabinofuranosyluracil [MeSH Supplementary Concept]
- 2'-deoxy-2'-fluoro-5-chloro-1-arabinofuranosyluracil [MeSH Supplementary Concept]
- 2-(4-(2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetoxy)-3,5-dihydroxyphenyl)-5,7-dihydroxy-4-oxochroman-3-yl-2-(5-fluoro-2-dihydropyrimidin-1(2H)-yl)acetate [MeSH Supplementary Concept]
- 2-(5-fluorouracil-1-yl)-5-hydroxymethyl-3-(uracil-1-yl)-1,4-dioxane [MeSH Supplementary Concept]
- 3-acetyl-5-fluorouracil [MeSH Supplementary Concept]
- 3alpha,17alpha,21-trihydroxy-5beta-pregnan-20-one-bis-5-fluorouracil [MeSH Supplementary Concept]
- 4-deoxy-5-fluorouracil [MeSH Supplementary Concept]
- 5,7-dihydroxy-4-oxo-2-(3,4,5-trihydroxyphenyl)chroman-3-yl-2-(5-fluoro-2,4-dioxo-3,4-dihydroxypyrimidin-1(2H)-yl)acetate [MeSH Supplementary Concept]
- 5-FU-CDDP protocol [MeSH Supplementary Concept]
- 5-FdU-alendronate [MeSH Supplementary Concept]
- 5-fluoro-1-((2-hydroxyethoxy)methyl)uracil [MeSH Supplementary Concept]
- 5-fluoro-1-(3,4-dideoxy-3-fluoro-6-O-trityl-glycero-hex-3-eno-pyranos-2-ulosyl) [MeSH Supplementary Concept]
- 5-fluoro-1-propargyluracil [MeSH Supplementary Concept]
- 5-fluoro-3-oxauracil [MeSH Supplementary Concept]
- 5-fluorodihydrouracil [MeSH Supplementary Concept]
- 5-fluorouracil dideoxyribonucleoside monophosphate [MeSH Supplementary Concept]
- 5-fluorouracil glucuronamide [MeSH Supplementary Concept]
- 5-fluorouracil glucuronide [MeSH Supplementary Concept]
- 5-fluorouracil tromethamine [MeSH Supplementary Concept]
- 5-fluorouracil, salicylic acid drug combination [MeSH Supplementary Concept]
- 5-fluorouracil-poly-alpha,beta-(2-hydroxyethyl)asparamide [MeSH Supplementary Concept]
- 5-fluorouracil-polysiloxane condensate [MeSH Supplementary Concept]
- 6-O-carboxymethylchitin-5-fluorouracil [MeSH Supplementary Concept]
- 6-fluorouracil [MeSH Supplementary Concept]
- 6-imidazolylmethyl-5-fluorouracil [MeSH Supplementary Concept]
- A-VBM-FH6 protocol [MeSH Supplementary Concept]
- ACMFVP protocol [MeSH Supplementary Concept]
- ALF protocol [MeSH Supplementary Concept]
- AMF protocol [MeSH Supplementary Concept]
- AVCF protocol [MeSH Supplementary Concept]
- AVLF protocol [MeSH Supplementary Concept]
- AVTMF protocol [MeSH Supplementary Concept]
- AcFuCy protocol [MeSH Supplementary Concept]
- B 3839 [MeSH Supplementary Concept]
- BAFMi protocol [MeSH Supplementary Concept]
- BFHM protocol [MeSH Supplementary Concept]
- CAF protocol [MeSH Supplementary Concept]
- CAF protocol 2 [MeSH Supplementary Concept]
- CAF-PH protocol [MeSH Supplementary Concept]
- CAFVP protocol [MeSH Supplementary Concept]
- CALF protocol [MeSH Supplementary Concept]
- CAMF protocol [MeSH Supplementary Concept]
- CAMFTP protocol [MeSH Supplementary Concept]
- CAPF protocol [MeSH Supplementary Concept]
- CEFT protocol [MeSH Supplementary Concept]
- CF protocol [MeSH Supplementary Concept]
- CF regimen [MeSH Supplementary Concept]
- CFB protocol [MeSH Supplementary Concept]
- CFMPV protocol [MeSH Supplementary Concept]
- CFP protocol [MeSH Supplementary Concept]
- CHAMP-5 protocol [MeSH Supplementary Concept]
- CHF protocol [MeSH Supplementary Concept]
- CIF protocol [MeSH Supplementary Concept]
- CMCF protocol [MeSH Supplementary Concept]
- CMF protocol [MeSH Supplementary Concept]
- CMF regimen [MeSH Supplementary Concept]
- CMF-B protocol [MeSH Supplementary Concept]
- CMFDV protocol [MeSH Supplementary Concept]
- CMFP protocol [MeSH Supplementary Concept]
- CMFPT protocol [MeSH Supplementary Concept]
- CMFPTH regimen [MeSH Supplementary Concept]
- CMFVP protocol [MeSH Supplementary Concept]
- CMxMF regimen [MeSH Supplementary Concept]
- COF protocol [MeSH Supplementary Concept]
- COFB protocol [MeSH Supplementary Concept]
- COFP protocol 1 [MeSH Supplementary Concept]
- COFP protocol 2 [MeSH Supplementary Concept]
- COMF protocol [MeSH Supplementary Concept]
- DF protocol [MeSH Supplementary Concept]
- DTIC-LVFU2 protocol [MeSH Supplementary Concept]
- EEPFL protocol [MeSH Supplementary Concept]
- EFP protocol [MeSH Supplementary Concept]
- ELF protocol [MeSH Supplementary Concept]
- ELFE regimen [MeSH Supplementary Concept]
- Emitefur [MeSH Supplementary Concept]
- F-FOMi protocol [MeSH Supplementary Concept]
- F-MACHOP protocol [MeSH Supplementary Concept]
- FAB protocol [MeSH Supplementary Concept]
- FAC-MV protocol [MeSH Supplementary Concept]
- FADIP protocol [MeSH Supplementary Concept]
- FAM protocol [MeSH Supplementary Concept]
- FAM-S protocol [MeSH Supplementary Concept]
- FAMMe protocol [MeSH Supplementary Concept]
- FAMP protocol [MeSH Supplementary Concept]
- FAMe protocol [MeSH Supplementary Concept]
- FAN regimen [MeSH Supplementary Concept]
- FAP protocol [MeSH Supplementary Concept]
- FAP2 protocol [MeSH Supplementary Concept]
- FAPEL protocol [MeSH Supplementary Concept]
- FCC protocol [MeSH Supplementary Concept]
- FCV protocol [MeSH Supplementary Concept]
- FDE protocol [MeSH Supplementary Concept]
- FDV protocol [MeSH Supplementary Concept]
- FEC protocol [MeSH Supplementary Concept]
- FEM protocol [MeSH Supplementary Concept]
- FEMP protocol [MeSH Supplementary Concept]
- FEMTX protocol [MeSH Supplementary Concept]
- FEMTX-P protocol [MeSH Supplementary Concept]
- FEN protocol [MeSH Supplementary Concept]
- FFG protocol [MeSH Supplementary Concept]
- FIB-P protocol [MeSH Supplementary Concept]
- FILM protocol [MeSH Supplementary Concept]
- FIM protocol [MeSH Supplementary Concept]
- FIVB+P protocol [MeSH Supplementary Concept]
- FLAP regimen [MeSH Supplementary Concept]
- FLEC protocol [MeSH Supplementary Concept]
- FLEP protocol [MeSH Supplementary Concept]
- FLEP regimen [MeSH Supplementary Concept]
- FLMP protocol [MeSH Supplementary Concept]
- FMC protocol [MeSH Supplementary Concept]
- FME protocol [MeSH Supplementary Concept]
- FMI protocol [MeSH Supplementary Concept]
- FML protocol [MeSH Supplementary Concept]
- FMN regimen [MeSH Supplementary Concept]
- FMP protocol [MeSH Supplementary Concept]
- FMT protocol [MeSH Supplementary Concept]
- FMVMP regimen [MeSH Supplementary Concept]
- FOAM protocol [MeSH Supplementary Concept]
- FOLFOX2-3 regimen [MeSH Supplementary Concept]
- FOLFOXIRI protocol [MeSH Supplementary Concept]
- FOLFUGEM protocol [MeSH Supplementary Concept]
- FOM protocol [MeSH Supplementary Concept]
- FONP protocol [MeSH Supplementary Concept]
- FPEPIR regimen [MeSH Supplementary Concept]
- FSM protocol [MeSH Supplementary Concept]
- FTM protocol [MeSH Supplementary Concept]
- FTP protocol [MeSH Supplementary Concept]
- FUFOX regimen [MeSH Supplementary Concept]
- FUM protocol [MeSH Supplementary Concept]
- FUVA protocol [MeSH Supplementary Concept]
- FVP protocol [MeSH Supplementary Concept]
- Folfox protocol [MeSH Supplementary Concept]
- Fu-CF protocol [MeSH Supplementary Concept]
- FuMi protocol [MeSH Supplementary Concept]
- GHVF protocol [MeSH Supplementary Concept]
- GOLF protocol [MeSH Supplementary Concept]
- GVF protocol [MeSH Supplementary Concept]
- HFAP protocol [MeSH Supplementary Concept]
- HLFP regimen [MeSH Supplementary Concept]
- HMF protocol [MeSH Supplementary Concept]
- HVF protocol [MeSH Supplementary Concept]
- HexMF protocol [MeSH Supplementary Concept]
- IFL protocol [MeSH Supplementary Concept]
- KAS 011 [MeSH Supplementary Concept]
- LCF protocol [MeSH Supplementary Concept]
- LMF protocol [MeSH Supplementary Concept]
- LMFP protocol [MeSH Supplementary Concept]
- M-FLP protocol [MeSH Supplementary Concept]
- MALF protocol [MeSH Supplementary Concept]
- MBCF protocol [MeSH Supplementary Concept]
- MCF protocol [MeSH Supplementary Concept]
- MFAV protocol [MeSH Supplementary Concept]
- MFC protocol [MeSH Supplementary Concept]
- MFL combination [MeSH Supplementary Concept]
- MFL protocol [MeSH Supplementary Concept]
- MFP protocol [MeSH Supplementary Concept]
- MMF protocol [MeSH Supplementary Concept]
- MOF protocol [MeSH Supplementary Concept]
- MOF-Strep protocol [MeSH Supplementary Concept]
- MOFK protocol [MeSH Supplementary Concept]
- MQF-OK protocol [MeSH Supplementary Concept]
- MQF-OK-FT protocol [MeSH Supplementary Concept]
- MQF-OK-UFT protocol [MeSH Supplementary Concept]
- MVF protocol [MeSH Supplementary Concept]
- MVPF protocol [MeSH Supplementary Concept]
- N(1)-(2-formylethyl)-5-fluorouracil [MeSH Supplementary Concept]
- N(1)-lauroylFU [MeSH Supplementary Concept]
- N(1)-octenoylFU [MeSH Supplementary Concept]
- N(1)-retinoylFU [MeSH Supplementary Concept]
- N-nicotinoylglycyl-2-(5-fluorouracil-1-yl)glycine [MeSH Supplementary Concept]
- N3-o-toluyl-fluorouracil [MeSH Supplementary Concept]
- N4SE protocol [MeSH Supplementary Concept]
- NF protocol [MeSH Supplementary Concept]
- NFO protocol [MeSH Supplementary Concept]
- NHO protocol [MeSH Supplementary Concept]
- NIACF regimen [MeSH Supplementary Concept]
- NMF protocol [MeSH Supplementary Concept]
- OFU 001 [MeSH Supplementary Concept]
- OGT 719 [MeSH Supplementary Concept]
- PAFT protocol [MeSH Supplementary Concept]
- PBMF protocol [MeSH Supplementary Concept]
- PCMF protocol [MeSH Supplementary Concept]
- PELF protocol 2 [MeSH Supplementary Concept]
- PFAP protocol [MeSH Supplementary Concept]
- PFL protocol [MeSH Supplementary Concept]
- PFL-MP protocol [MeSH Supplementary Concept]
- PFLI-alpha protocol [MeSH Supplementary Concept]
- PFT protocol [MeSH Supplementary Concept]
- PIAF regimen [MeSH Supplementary Concept]
- PM-FAC protocol [MeSH Supplementary Concept]
- PMF protocol [MeSH Supplementary Concept]
- PMFV protocol [MeSH Supplementary Concept]
- PMUE protocol 2 [MeSH Supplementary Concept]
- PNMF protocol [MeSH Supplementary Concept]
- Price-Hill protocol [MeSH Supplementary Concept]
- R-14 regimen [MeSH Supplementary Concept]
- SUPERFAN regimen [MeSH Supplementary Concept]
- TAC 278 [MeSH Supplementary Concept]
- TCF protocol [MeSH Supplementary Concept]
- THP-FLPM protocol [MeSH Supplementary Concept]
- TMF protocol [MeSH Supplementary Concept]
- TNCF regimen [MeSH Supplementary Concept]
- TPDC-FuHu protocol [MeSH Supplementary Concept]
- TPF protocol [MeSH Supplementary Concept]
- TPFL4 regimen [MeSH Supplementary Concept]
- TPFL5 protocol [MeSH Supplementary Concept]
- UK 25 [MeSH Supplementary Concept]
- VBCMF protocol [MeSH Supplementary Concept]
- VBMF protocol [MeSH Supplementary Concept]
- VEMFAH protocol [MeSH Supplementary Concept]
- VFP protocol [MeSH Supplementary Concept]
- VIF protocol [MeSH Supplementary Concept]
- VMF protocol [MeSH Supplementary Concept]
- VMF regimen [MeSH Supplementary Concept]
- VMP-CIsCF protocol [MeSH Supplementary Concept]
- VTMF protocol [MeSH Supplementary Concept]
- VTMFAP protocol [MeSH Supplementary Concept]
- VTMFP protocol [MeSH Supplementary Concept]
- VbCFM protocol [MeSH Supplementary Concept]
- ViFuP protocol [MeSH Supplementary Concept]
- XELOX [MeSH Supplementary Concept]
- alpha-tocopherol-5-fluorouracil [MeSH Supplementary Concept]
- antitumor B III [MeSH Supplementary Concept]
- atofluding [MeSH Supplementary Concept]
- capecitabine-irinotecan combination [MeSH Supplementary Concept]
- carmofur [MeSH Supplementary Concept]
- chlorobenly-5-fluorouracil porphyrin [MeSH Supplementary Concept]
- fluorouracil-acetic-acid-dextran conjugate [MeSH Supplementary Concept]
- folfirinox [MeSH Supplementary Concept]
- half protocol [MeSH Supplementary Concept]
- hexa CAF protocol [MeSH Supplementary Concept]
- indolacin 5-fluorouracil-1-ylmethyl ester [MeSH Supplementary Concept]
- magnizil [MeSH Supplementary Concept]
- mallinson protocol [MeSH Supplementary Concept]
- methyl 1-(5-fluoro-1H-2-oxopyrimidin-4-yl)-beta-D- glucopyranuronate [MeSH Supplementary Concept]
- opTPFL regimen [MeSH Supplementary Concept]
- regimen B [MeSH Supplementary Concept]
- schSFPEG 5-fluorouracil [MeSH Supplementary Concept]
- technetium 99m 5-fluorouracil [MeSH Supplementary Concept]
Semantic type(s)
- Nucleic Acid, Nucleoside, or Nucleotide [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Fluorouracil [ICD-11 Extension code]
- Fluorouracil [NCIt concept]
- Fluorouracil [LOINC component]
- Fluorouracil (substance) [SNOMED CT concept]
- Product containing fluorouracil (medicinal product) [SNOMED CT concept]
- fluorouracil [ATC Code]
- fluorouracil [Substance BNPC]
- fluorouracil [SNOMED Notion]
Validated automatic mappings to BTNT
- fluorouracil [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients